A novel psychedelic 5-HT2A receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer

Gerard J. Marek, Soma Makai-Bölöni, Daniel Umbricht, Edward P. Christian, Jason Winters, Dino Dvorak, Shane Raines, Zoë A. Hughes, Eric W. Austin, Adam K. Klein, William Leong, Fas J. Krol, Anne J. van der Graaf, Maria J. Juachon, Marije E. Otto, Laura G. J, Gabriël Jacobs, Andrew C. Kruegel, Jonathan Sporn

Journal of Psychopharmacology

Published online on October 16, 2025

Abstract

Journal of Psychopharmacology, Ahead of Print.
Background:The treatment of major depressive disorder (MDD) with available antidepressant drugs is characterized by considerable ineffectiveness. Classical psychedelics such as psilocybin and N,N-dimethyltryptamine (DMT), which act primarily as 5-...